Climb Bio (CLYM) EBITDA Yield: History & Chart

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T14:56:23.021Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:56:23.021Z.

Quote observation: 2026-10-06T14:55:20.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -64,628,000
Quote market capitalization: 636,478,245
Total debt · period ending 2026-06-30: 1,314,000
Cash · period ending 2026-06-30: 44,107,000

FMP input reference: 979ff17a100a324a490b4ea8bab969f4c23ca35a684dd985742eca9c7cd70937

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

CLYM EBITDA Yield Metrics

EBITDA YIELD

N/A

CLYM Competitors' EBITDA Yield

CLYM

Climb Bio, Inc.

Current

Market Cap

$636.48M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AURA

Aura Biosciences, Inc.

vs CLYM

Market Cap

$640.57M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OABI

OmniAb, Inc.

vs CLYM

Market Cap

$643.45M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ANGO

AngioDynamics, Inc.

vs CLYM

Market Cap

$610.07M

EBITDA Yield

N/A

TTM Avg

11.92%

3Y Avg

8.30%

5Y Avg

4.40%

MDXG

MiMedx Group, Inc.

vs CLYM

Market Cap

$665.40M

EBITDA Yield

3.84%

TTM Avg

10.03%

3Y Avg

6.88%

5Y Avg

6.20%

FDMT

4D Molecular Therapeutics, Inc.

vs CLYM

Market Cap

$666.36M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HELP

Helus Pharma Inc.

vs CLYM

Market Cap

$666.95M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FLGT

Fulgent Genetics, Inc.

vs CLYM

Market Cap

$600.96M

EBITDA Yield

N/A

TTM Avg

41.20%

3Y Avg

25.05%

5Y Avg

21.67%

IRWD

Ironwood Pharmaceuticals, Inc.

vs CLYM

Market Cap

$597.83M

EBITDA Yield

25.99%

TTM Avg

14.91%

3Y Avg

12.56%

5Y Avg

12.68%

ANNX

Annexon, Inc.

vs CLYM

Market Cap

$679.13M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Climb Bio, Inc. (CLYM)	$636.48M	N/A	N/A	N/A	N/A
Aura Biosciences, Inc. (AURA)vs ›	$640.57M	N/A	N/A	N/A	N/A
OmniAb, Inc. (OABI)vs ›	$643.45M	N/A	N/A	N/A	N/A
AngioDynamics, Inc. (ANGO)vs ›	$610.07M	N/A	11.92%	8.30%	4.40%
MiMedx Group, Inc. (MDXG)vs ›	$665.40M	3.84%	10.03%	6.88%	6.20%
4D Molecular Therapeutics, Inc. (FDMT)vs ›	$666.36M	N/A	N/A	N/A	N/A
Helus Pharma Inc. (HELP)vs ›	$666.95M	N/A	N/A	N/A	N/A
Fulgent Genetics, Inc. (FLGT)vs ›	$600.96M	N/A	41.20%	25.05%	21.67%
Ironwood Pharmaceuticals, Inc. (IRWD)vs ›	$597.83M	25.99%	14.91%	12.56%	12.68%
Annexon, Inc. (ANNX)vs ›	$679.13M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

CLYM EBITDA Yield Metrics

CLYM Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics